Olema Pharmaceuticals, Inc. NASDAQ:OLMA

Olema Pharmaceuticals stock price today

$5.51
-0.64
-10.41%
Financial Health
0
1
2
3
4
5
6
7
8
9

Olema Pharmaceuticals stock price monthly change

-50.00%
month

Olema Pharmaceuticals stock price quarterly change

-50.00%
quarter

Olema Pharmaceuticals stock price yearly change

-57.73%
year

Olema Pharmaceuticals key metrics

Market Cap
354.67M
Enterprise value
110.84M
P/E
-1.34
EV/Sales
N/A
EV/EBITDA
-1.06
Price/Sales
N/A
Price/Book
0.66
PEG ratio
0.02
EPS
-2.02
Revenue
N/A
EBITDA
-109.33M
Income
-99.33M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Olema Pharmaceuticals stock price history

Olema Pharmaceuticals stock forecast

Olema Pharmaceuticals financial statements

Average Price Target
Last Year

$27

Potential upside: 390.01%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): Profit margin
Jun 2023 0 -20.09M
Sep 2023 0 -21.50M
Dec 2023 1.88M -26.77M -1421.02%
Mar 2024 0 -30.97M
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): Debt to assets
Jun 2023 177624000 16.04M 9.03%
Sep 2023 292799000 17.66M 6.03%
Dec 2023 276945000 23.05M 8.32%
Mar 2024 263694000 27.37M 10.38%
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): Cash Flow
Jun 2023 -22.11M 14.11M 2.04M
Sep 2023 -22.74M -25.43M 130.62M
Dec 2023 -18.47M -30.91M 523K
Mar 2024 -23.49M -20.14M 8.82M

Olema Pharmaceuticals alternative data

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): Employee count
Aug 2023 62
Sep 2023 67
Oct 2023 67
Nov 2023 67
Dec 2023 70
Jan 2024 70
Feb 2024 70
Mar 2024 74
Apr 2024 74
May 2024 74
Jun 2024 75
Jul 2024 75

Olema Pharmaceuticals other data

14.41% -68.67%
of OLMA is owned by hedge funds
5.76M -27.49M
shares is hold by hedge funds

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 25000
Feb 2024 0 30000
Mar 2024 0 20000
Apr 2024 0 15000
May 2024 0 20000
Jun 2024 0 1205000
Jul 2024 0 10000
Aug 2024 0 2400000
Dec 2024 700761 894978
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
GRAHAM G. WALMSLEY director
Common Stock 700,761 $6.75 $4,730,137
Sale
GRAHAM G. WALMSLEY director
Common Stock 700,761 $6.75 $4,730,137
Option
ZOJWALLA NASEEM officer: CHIEF MEDICAL OFFICER
Common Stock 14,000 $4.87 $68,180
Option
ZOJWALLA NASEEM officer: CHIEF MEDICAL OFFICER
Stock Option (Right to Buy) 14,000 $4.87 $68,180
Sale
KOVACS SHANE WILLIAM CHARLES officer: CH. OPERATING & FINANC..
Common Stock 17,950 $8.66 $155,447
Sale
KOVACS SHANE WILLIAM CHARLES officer: CH. OPERATING & FINANC..
Common Stock 406 $9.39 $3,812
Sale
BOHEN SEAN director, officer.. Common Stock 55,907 $8.66 $484,155
Sale
BOHEN SEAN director, officer.. Common Stock 1,267 $9.39 $11,897
Sale
HARMON CYRUS director Common Stock 7,958 $8.66 $68,916
Sale
HARMON CYRUS director Common Stock 179 $9.39 $1,681
Patent
Application
Filling date: 6 Jul 2020 Issue date: 25 Aug 2022
Grant
Filling date: 17 Apr 2020 Issue date: 25 Jan 2022
Application
Filling date: 17 Apr 2020 Issue date: 4 Mar 2021
Grant
Filling date: 23 Apr 2019 Issue date: 21 Apr 2020
Application
Filling date: 23 Apr 2019 Issue date: 15 Aug 2019
Tuesday, 10 December 2024
globenewswire.com
Monday, 9 December 2024
globenewswire.com
Tuesday, 3 December 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Tuesday, 12 November 2024
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Monday, 4 November 2024
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
Wednesday, 9 October 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Wednesday, 4 September 2024
globenewswire.com
Wednesday, 21 August 2024
globenewswire.com
Tuesday, 2 July 2024
globenewswire.com
Wednesday, 5 June 2024
finbold.com
Tuesday, 4 June 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
globenewswire.com
Thursday, 2 May 2024
globenewswire.com
Wednesday, 1 May 2024
GlobeNewsWire
Monday, 8 April 2024
GlobeNewsWire
Tuesday, 6 February 2024
GlobeNewsWire
Tuesday, 2 January 2024
GlobeNewsWire
Tuesday, 28 November 2023
GlobeNewsWire
Seeking Alpha
Monday, 27 November 2023
Zacks Investment Research
Wednesday, 1 November 2023
GlobeNewsWire
Monday, 30 October 2023
Zacks Investment Research
Wednesday, 11 October 2023
Zacks Investment Research
  • What's the price of Olema Pharmaceuticals stock today?

    One share of Olema Pharmaceuticals stock can currently be purchased for approximately $5.51.

  • When is Olema Pharmaceuticals's next earnings date?

    Unfortunately, Olema Pharmaceuticals's (OLMA) next earnings date is currently unknown.

  • Does Olema Pharmaceuticals pay dividends?

    No, Olema Pharmaceuticals does not pay dividends.

  • How much money does Olema Pharmaceuticals make?

    Olema Pharmaceuticals has a market capitalization of 354.67M.

  • What is Olema Pharmaceuticals's stock symbol?

    Olema Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "OLMA".

  • What is Olema Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Olema Pharmaceuticals?

    Shares of Olema Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Olema Pharmaceuticals's key executives?

    Olema Pharmaceuticals's management team includes the following people:

    • Dr. Cyrus L. Harmon Ph.D. Chief Technology Officer & Director(age: 54, pay: $657,990)
    • Dr. Sean P. Bohen Pres, Chief Executive Officer & Director(age: 58, pay: $643,090)
    • Mr. John B. Moriarty Jr. Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 57, pay: $434,320)
    • Dr. Peter J. Kushner Ph.D. Chief Scientific Officer(age: 86, pay: $429,950)
  • How many employees does Olema Pharmaceuticals have?

    As Jul 2024, Olema Pharmaceuticals employs 75 workers, which is 1% more then previous quarter.

  • When Olema Pharmaceuticals went public?

    Olema Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 19 Nov 2020.

  • What is Olema Pharmaceuticals's official website?

    The official website for Olema Pharmaceuticals is olema.com.

  • Where are Olema Pharmaceuticals's headquarters?

    Olema Pharmaceuticals is headquartered at 512 2nd Street, San Francisco, CA.

  • How can i contact Olema Pharmaceuticals?

    Olema Pharmaceuticals's mailing address is 512 2nd Street, San Francisco, CA and company can be reached via phone at +65 02435555.

  • What is Olema Pharmaceuticals stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Olema Pharmaceuticals in the last 12 months, the avarage price target is $27. The average price target represents a 390.01% change from the last price of $5.51.

Olema Pharmaceuticals company profile:

Olema Pharmaceuticals, Inc.

olema.com
Exchange:

NASDAQ

Full time employees:

74

Industry:

Biotechnology

Sector:

Healthcare

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

512 2nd Street
San Francisco, CA 94107

CIK: 0001750284
ISIN: US68062P1066
CUSIP: 68062P106